Lyric, a health care payment accuracy company based in Philadelphia and Nashville, said on July 15, 2026 that it had acquired Concert, a company that turns clinical and coverage policies into machine-readable rules used to make claim and payment decisions in real time.
Financial terms were not disclosed. The two companies had worked together since 2023, and Lyric said the scope and use of their joint product had grown nearly tenfold over that time.
Concert's technology will be built into Lyric42, Lyric's AI platform for health plans. Its existing Diagnostics Module, which handles policy and claim editing for all outpatient laboratory tests, will be extended across Lyric's full client base, with more areas planned.
What Concert built
Concert was founded in 2010 under the name NextGxDx by Mark Harris, a cancer biologist trained at Vanderbilt University. Its first product, GeneConnect, helped hospitals manage the ordering of genetic tests and drew on a database that held about 35,000 tests by 2015. Hospitals paid to license the platform, and laboratories paid when their tests were ordered through it. It renamed itself Concert Genetics in March 2017 and has used the name Concert since 2024.
Over time the company moved from ordering into payment. It now combines its own market data, clinical and coding experts and patented technology to cover diagnostic test ordering, results, coding, coverage, claim editing and payment integrity.
Its central idea is that coverage policy should be written in a form computers can apply. Instead of staff checking claims against written policies at separate points in the process, Concert encodes the rules so health plans and providers can apply the same evidence-based standards inside the systems they already use.
“Concert was built on the conviction that clinical and administrative policy should be transparent, evidence-based, and computable, delivered into the systems that health plans and providers actually use to make decisions. Combining with Lyric allows us to deliver at scale through the Lyric42 platform. Together, we can extend intelligence across the workflows where healthcare decisions are made.”
Why Lyric is buying
Lyric said its Lyric42 platform is used by nine of the ten largest US health plans to check payment accuracy as claims are processed, and that it supports 200 million covered lives. The company says it combines clinical, regulatory and policy expertise with AI to produce payment decisions that can be audited.
The case for the deal rests on the growing number of genetic tests, precision diagnostics, personalised therapies and specialty drugs, which make coverage rules harder for health plans to keep current by hand. Lyric said Concert's approach would let plans move from enforcing rules after the fact to shared standards agreed with providers before claims are submitted.
Chief executive Halsey Wise said that combining Concert's precision medicine capabilities with Lyric's platform would give health plan clients important insights. President and chief financial officer Ravi Umarji said the approach would replace enforcement at disconnected checkpoints with shared standards that bring transparency to plans, providers and members.
The founders and the funding
Concert has been led since July 2016 by chief executive Rob Metcalf, a former president of Digital Reasoning. Harris moved to the role of chief innovation officer when Metcalf joined, Venture Nashville reported.
By 2015 it had raised more than $5 million through seed, Series A and Series B rounds from about 50 shareholders, including Abstraction Ventures, Nashville Capital Network and the accelerator Jumpstart Foundry, where Harris first tested the idea in 2010 and 2011. By mid-2016 it had raised more than $8 million in total.
Metcalf said Concert was built on the belief that clinical and administrative policy should be transparent, evidence-based and computable, and that joining Lyric would let it deliver that at scale.
What happens to customers
For health plans that already use Lyric, the main change is wider access to Concert's laboratory testing rules, which until now were offered as a joint product. Lyric said further expansions of scope are planned beyond lab tests.
Providers and patients are meant to benefit too. Lyric said shared, machine-readable policies would bring transparency and alignment to health plans, their network providers and the members they serve, with standards set before claims are submitted.
